NCT00225147View on ClinicalTrials.gov

Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

October 31, 2009

Study Completion Date

January 31, 2010

Conditions
Hereditary AngioedemaAngioneurotic Edema
Interventions
DRUG

Recombinant Human C1 Inhibitor

IV

DRUG

placebo

saline solution

Trial Locations (1)

2300 AL

For information on sites please contact Pharming Medical Affairs Department, Leiden

Sponsors
All Listed Sponsors
lead

Pharming Technologies B.V.

INDUSTRY

NCT00225147 - Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema | Biotech Hunter | Biotech Hunter